Relief Therapeutics Holding (Relief Therapeutics Holding) FCF Margin %

: -358.47% (As of Jun. 2023)

View and export this data going back to 1990. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Relief Therapeutics Holding's Free Cash Flow for the six months ended in Jun. 2023 was $-12.03 Mil. Relief Therapeutics Holding's Revenue for the six months ended in Jun. 2023 was $3.36 Mil. Therefore, Relief Therapeutics Holding's FCF Margin % for the quarter that ended in Jun. 2023 was -358.47%.

As of today, Relief Therapeutics Holding's current FCF Yield % is -135.66%.

The historical rank and industry rank for Relief Therapeutics Holding's FCF Margin % or its related term are showing as below:

RLFTF' s FCF Margin % Range Over the Past 10 Years
Min: -1488.29 Med: -257.35 Max: -46.64
Current: -351.92

During the past 13 years, the highest FCF Margin % of Relief Therapeutics Holding was -46.64%. The lowest was -1488.29%. And the median was -257.35%.

RLFTF's FCF Margin % is ranked worse than
61.71% of 1029 companies
in the Biotechnology industry
Industry Median: -149.8 vs RLFTF: -351.92

Relief Therapeutics Holding FCF Margin % Historical Data

The historical data trend for Relief Therapeutics Holding's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

-109.30

-1,488.24

-405.33

Relief Therapeutics Holding Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Margin %																-	-541.68	-458.38	-344.70	-358.47

Competitive Comparison

For the Biotechnology subindustry, Relief Therapeutics Holding's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relief Therapeutics Holding FCF Margin % Distribution

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's FCF Margin % falls into.

Relief Therapeutics Holding FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Relief Therapeutics Holding's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-26.456	/	6.527
	=	-405.33 %

Relief Therapeutics Holding's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-12.034	/	3.357
	=	-358.47 %

Relief Therapeutics Holding FCF Margin % Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK RLF:Switzerland

Address

Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.